Welcome to Booking Holdings third quarter 2024 conference call. Booking Holdings would like to remind everyone that this call may contain forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guaranteed of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially from these express ...

Good day, everyone, and welcome to today's GitLab third quarter fiscal year 2025 conference call. At this time, all participants are in view and listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. If you'd like to ask a question, please use the raise hand function located in the menu of your Zoom controls at the bottom of your screen. In addition, please ensure your Zoom name reflects your full name and the firm you are joined with. And if you are ...

earnings conference call. My name is Sarah and I will be your conference operator today. As a reminder, this conference is being recorded. I would now like to turn the program over to your host for today's conference, Steve Winokur, PayPal's Chief Investor Relations Officer. Please go ahead. Thanks, Sarah. Welcome to PayPal's third quarter 2024 earnings call. I'm joined by CEO Alex Criss and CFO Jamie Miller. Our remarks today include forward-looking statements that involve risks and uncertainties. Actual r ...

Good afternoon. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to the MEDA third quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, again, press star one. We ask that you limit yourself to one question. This ca ...

At this time, all participants are in a listen-only mode. Greetings and welcome to the AMD third quarter 2024 conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. And as a reminder, this conference is being recorded. It is now my pleasure to You may begin. Thank you and welcome to AMD's third quarter 2024 financial results con ...

Hello, everyone, and welcome to Asana's third quarter fiscal year 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To participate, you will need to press star 11 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, simply press star 11 again. Please be advised that today's conference is being recorded. Now we'll pass the call over to the Head of Inve ...

Summary of Moderna, Inc. Conference Call Company Overview - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Industry**: Biotechnology, specifically focusing on mRNA vaccines and medicines - **Event**: Piper Sandler 36th Annual Healthcare Conference - **Date**: December 5, 2024 Key Points and Arguments Current Position and Market Dynamics - Moderna is recognized as a leading developer of mRNA vaccines and medicines, currently in a strong position with a robust balance sheet and a de-risked mRNA technology platform [2][2] - The company is preparing for several approvals in its late-stage clinical pipeline over the coming years [2][2] COVID-19 Vaccination and Future Products - The company is focused on increasing COVID vaccination rates, particularly among the elderly, who are at higher risk for hospitalization [8][8] - Moderna's next-generation vaccine, mRNA-1283, is expected to have higher efficacy than its previous product, Spikevax, and is aimed at the elderly population [13][14] - The combination vaccine for COVID and flu is anticipated to be crucial in preventing hospitalizations and saving costs [12][12] RSV Vaccine Launch and Market Strategy - Moderna's RSV vaccine, mRESVIA, is entering a market with significant unmet medical needs, particularly for the elderly and pediatric populations [21][22] - The company acknowledges a slower uptake compared to competitors Pfizer and GSK, attributing this to logistical challenges and timing of market entry [31][32] - Future strategies include bundling vaccines to enhance sales and market penetration [34][35] Cytomegalovirus (CMV) Vaccine Development - Moderna is developing a CMV vaccine, which addresses a significant public health issue, particularly in preventing birth defects [36][37] - The CMV vaccine is seen as a potential $2 billion to $5 billion annual market opportunity, with plans to expand its use to pediatric settings [58][58] - The company is preparing educational campaigns targeting OB/GYNs and the general public to raise awareness about CMV and the vaccine [54][56] Safety and Efficacy Considerations - Moderna's RSV vaccine is expected to have a favorable safety profile compared to competitors, as it has not reported cases of Guillain-Barré syndrome in its Phase 3 studies [30][30] - The company emphasizes the importance of data transparency and public health recommendations to encourage vaccination [9][9] Financial Implications - The next-generation COVID vaccine is expected to command a premium price due to its higher efficacy, benefiting both Moderna and retail partners [15][17] - The use of existing manufacturing capacity for the CMV vaccine is projected to yield high gross margins, enhancing the company's financial outlook [60][60] Additional Important Insights - The company is actively working to counter misinformation surrounding vaccines and is committed to transparency in data sharing [9][9] - Moderna's strategy includes leveraging its mRNA technology to create combination vaccines, which could simplify vaccination processes and improve public health outcomes [12][12] - The company is poised to capitalize on the growing demand for vaccines, particularly in the context of respiratory diseases, which are significant health threats in the U.S. [11][11]

Danaher Corporation (NYSE:DHR) Conference Call Summary Company Overview - **Company**: Danaher Corporation - **Event**: Annual Evercore ISI HealthCONx Healthcare Conference - **Date**: December 4, 2024 - **Participants**: Rainer Blair (President and CEO), Vijay Kumar (Evercore ISI Life Science Device Analyst) Key Points Industry and Company Performance - **Third Quarter Performance**: Danaher reported a solid performance in Q3, with both Cepheid and bioprocessing outperforming expectations. Life Science and diagnostics businesses met expectations, indicating strong underlying drivers continuing into Q4 [5][11][15]. - **Bioprocessing Growth**: The company has seen five consecutive quarters of sequential orders growth, with high single-digit growth in Q3. The book-to-bill ratio has been near one, indicating stable order flow [15][20]. Market Dynamics - **China Tariffs and Manufacturing**: Danaher primarily manufactures in China for local supply, indicating a region-for-region supply chain. The company is prepared to manage potential impacts from political changes and tariffs [6][12]. - **NIH Exposure**: Less than 5% of Danaher's business is related to academic and research, with less than 1% tied to NIH funding, suggesting limited exposure to potential funding cuts [10]. Customer Segmentation - **Customer Base**: Approximately 75% of Danaher's business comes from large customers with commercial programs, while 20-25% is from smaller customers. Larger customers have returned to normal ordering patterns, while smaller customers are more cautious with funding [16][18]. M&A Landscape - **M&A Activity**: The company is positioned well for potential M&A opportunities, focusing on smaller to medium-sized bolt-on deals due to high market multiples [12][13]. Bioprocessing and Market Outlook - **Gradual Recovery**: Danaher anticipates a gradual recovery in biopharma, supported by strong demand for monoclonal antibodies. The company expects continued growth in the bioprocessing market, projecting high single-digit growth long-term [22][25]. - **China Market**: The Chinese market is currently at a lower activity level due to constrained venture capital and regulatory challenges. Danaher expects a return to historical growth rates over time [30][31]. Diagnostics Segment - **Non-Respiratory Growth**: The non-respiratory diagnostics business has seen significant growth, driven by an expanded installed base and new assay launches. The penetration of molecular diagnostics is below 40%, indicating room for future growth [42][45]. - **Respiratory Business**: The respiratory diagnostics segment is projected to stabilize at an endemic level of $1.5 billion to $1.6 billion, with ongoing improvements in testing capabilities [48][49]. Financial Metrics and Guidance - **Margins and Incrementals**: Danaher expects operating margins in the low- to mid-30s with incrementals of 35% to 40% as growth rates approach high single digits [77]. - **Fiscal 2025 Considerations**: Key factors for 2025 include order book development, the impact of potential stimulus in China, and foreign exchange rates [80][82]. Innovation and Future Growth - **Beckman Diagnostics**: The Beckman segment is expected to accelerate growth due to strong patient volumes, innovative products, and improved commercial execution [53][56]. - **Digital Diagnostics**: Leica Biosystems is positioned well in digital diagnostics, with ongoing developments in AI and digital support for pathologists [60][62]. Additional Insights - **Liquid Biopsy Interest**: Danaher is exploring opportunities in cancer diagnostics, including liquid biopsy, as part of its broader strategy to enhance diagnostic capabilities [63]. - **Instrumentation Growth**: The instrumentation segment has shown signs of stabilization, with expectations for growth in the coming year [64][68]. This summary encapsulates the key insights and strategic outlook from Danaher Corporation's recent conference call, highlighting the company's performance, market dynamics, and future growth opportunities.

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|-------|-------------------------------------------------------------------------------------|-----------------------------------------|----------------------------|-------------------- ...

M Update Clean Tech | North America Morgan Stanley & Co. LLC Andrew S Percoco The Department of Commerce (DoC) published a preliminary affirmative determination in the 2024 Solar Anti-Dumping investigation. Preliminary general tariff rates include 271% for Vietnam, 117% for Cambodia, 58% for Thailand, and 18% for Malaysia - a full list of subsidy rates by country and company can be found in Exhibit 1 - 4. Note that the DoC preliminarily affirmed critical circumstances for Vietnam and Thailand, which introdu ...